MYC

Summary

MYC (MYC proto-oncogene, bHLH transcription factor, HGNC:7553) is a protein-coding gene on chromosome 8q24.21, encoding Myc proto-oncogene protein (P01106). Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5’-CAC[GA]TG-3’. In precision oncology, MYC Overexpression confers sensitivity to Ganetespib in Esophagus Squamous Cell Carcinoma (CIViC Level D); 2 further curated variant–drug associations are listed below. It is a common-essential gene (DepMap: required in 95.2% of cancer cell lines).

This gene is a proto-oncogene and encodes a nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. The encoded protein forms a heterodimer with the related transcription factor MAX. This complex binds to the E box DNA consensus sequence and regulates the transcription of specific target genes. Amplification of this gene is frequently observed in numerous human cancers. Translocations involving this gene are associated with Burkitt lymphoma and multiple myeloma in human patients. There is evidence to show that translation initiates both from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site, resulting in the production of two isoforms with distinct N-termini.

Source: NCBI Gene 4609 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Burkitt lymphoma (No Known Disease Relationship, GenCC)
• GWAS associations: 51
• Clinical variants (ClinVar): 49 total — 5 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 18
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• Precision-oncology evidence (CIViC): 3 curated variant–drug associations
• Cancer driver (intOGen): activating (oncogene-like) across 4 cancer types
• Cancer dependency (DepMap): dependent in 95.2% of screened cell lines (common-essential)
• Transcription factor: yes — 929 downstream targets (CollecTRI)
• MANE Select transcript: NM_002467

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7553
Approved symbol	MYC
Name	MYC proto-oncogene, bHLH transcription factor
Location	8q24.21
Locus type	gene with protein product
Status	Approved
Aliases	c-Myc, bHLHe39, MYCC
Ensembl gene	ENSG00000136997
Ensembl biotype	protein_coding
OMIM	190080
Entrez	4609

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 13 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000259523, ENST00000377970, ENST00000517291, ENST00000520751, ENST00000524013, ENST00000621592, ENST00000641036, ENST00000641252, ENST00000651626, ENST00000652288, ENST00000707113, ENST00000707114, ENST00000707115, ENST00000707116, ENST00000707117

RefSeq mRNA: 2 — MANE Select: NM_002467 NM_001354870, NM_002467

CCDS: CCDS6359, CCDS87627

Canonical transcript exons

ENST00000621592 — 3 exons

Exon	Start	End
ENSE00003475084	127738248	127739019
ENSE00003746860	127736231	127736623
ENSE00003847400	127740396	127742951

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 99.12.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 191.5817 / max 3848.3245, expressed in 1819 samples.

FANTOM5 promoters (14 alternative TSS)

Promoter ID	TPM avg	Samples expressed
90656	138.5911	1814
90655	43.1267	1715
90658	2.9598	1372
90664	1.2720	841
90650	1.1301	427
90653	0.9416	401
90671	0.7189	400
90663	0.6612	395
90654	0.5908	150
90672	0.3948	195

Top tissues by expression

282 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
upper leg skin	UBERON:0004262	99.12	gold quality
vena cava	UBERON:0004087	99.08	gold quality
left uterine tube	UBERON:0001303	98.80	gold quality
skin of abdomen	UBERON:0001416	98.56	gold quality
mucosa of stomach	UBERON:0001199	98.26	gold quality
penis	UBERON:0000989	98.18	gold quality
peritoneum	UBERON:0002358	97.68	gold quality
omental fat pad	UBERON:0010414	97.68	gold quality
mucosa of urinary bladder	UBERON:0001259	97.59	gold quality
skin of leg	UBERON:0001511	97.54	gold quality
pericardium	UBERON:0002407	97.34	gold quality
gall bladder	UBERON:0002110	97.31	gold quality
adipose tissue of abdominal region	UBERON:0007808	96.85	gold quality
zone of skin	UBERON:0000014	96.75	gold quality
cartilage tissue	UBERON:0002418	96.67	gold quality
mammary duct	UBERON:0001765	96.66	gold quality
nipple	UBERON:0002030	96.19	gold quality
right ovary	UBERON:0002118	96.08	gold quality
left ovary	UBERON:0002119	95.95	gold quality
esophagus mucosa	UBERON:0002469	95.81	gold quality
epithelium of mammary gland	UBERON:0003244	95.65	gold quality
parotid gland	UBERON:0001831	95.62	gold quality
trachea	UBERON:0003126	95.53	gold quality
synovial joint	UBERON:0002217	95.20	gold quality
skin of hip	UBERON:0001554	95.18	gold quality
pharyngeal mucosa	UBERON:0000355	94.93	gold quality
subcutaneous adipose tissue	UBERON:0002190	94.77	gold quality
mammalian vulva	UBERON:0000997	94.76	gold quality
body of pancreas	UBERON:0001150	94.68	gold quality
vermiform appendix	UBERON:0001154	94.67	gold quality

Single-cell (SCXA)

Detected in 20 experiment(s), a significant marker in 16.

Experiment	Marker?	Max mean expression
E-HCAD-24	yes	1374.62
E-CURD-112	yes	830.13
E-MTAB-10432	yes	395.11
E-MTAB-8271	yes	316.79
E-MTAB-6701	yes	114.92
E-HCAD-6	yes	65.13
E-HCAD-4	yes	30.61
E-MTAB-9067	yes	23.43
E-MTAB-10042	yes	14.86
E-GEOD-125970	yes	11.41
E-GEOD-81547	yes	10.82
E-GEOD-130148	yes	8.84
E-MTAB-10553	yes	6.92
E-MTAB-9801	yes	6.35
E-GEOD-93593	yes	5.98

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

929 targets.

Target	Regulation
ABCA4
ABCB1	Unknown
ABCB6
ABI2	Repression
ABL1
ACADM	Unknown
ACE	Unknown
ACHE
ACO2	Unknown
ACOX1	Unknown
ACP3	Unknown
ACP5	Unknown
ACSL4	Repression
ACTB
ACTG1	Unknown
ACTG2
ACTL6A
ACYP2	Unknown
ADAM2
ADCY9	Unknown
ADM	Unknown
ADRB1	Activation
ADSL	Activation
AFP
AGO1
AGTR1
AHSG	Unknown
AIMP2	Activation
AKAP1	Unknown
AKR1A1	Unknown

JASPAR motifs

Motif	Name	Family
MA0059.1	MAX::MYC	bHLH-ZIP
MA0059.2	MAX::MYC	bHLH-ZIP
MA0147.3	MYC	bHLH-ZIP
MA0147.4	MYC	bHLH-ZIP

JASPAR matrix evidence (PMIDs): PMID:8265351, PMID:18555785

Upstream regulators (CollecTRI, top): AATF, AHR, AHRR, AP1, APC, AR, ARID5B, BCL6, BDP1, BIN1, BRCA1, CDC73, CDKN1A, CEBPA, CEBPB, CEBPE, CHD8, CLDN19, CLDN3, CNBP, CREBBP, CTCF, CTCFL, CTNNB1, CUX1, DLX2, DLX4, DLX5, E2F1, E2F4, E2F5, EGR1, ELF1, ENO1, EP300, EPCAM, ERF, ERG, ESR1, ESR2

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 95.2% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 40)

• Review: EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt’s lymphoma (PMID:11443860)
• We have located a region in the c-myc promoter that is required for the complete activation by the immunoglobulin heavy chain gene enhancer (PMID:11777933)
• In Situ studies demonstrate enhanced mRNA expression of the proto-oncogene c-myc in stenotic venous bypass grafts. (PMID:11795828)
• c-Myc physically interacts with Smad2 and Smad3 involved in TGF-beta signaling.c-Myc promotes cell growth and cancer development partly by inhibiting the growth inhibitory functions of Smads (PMID:11804592)
• Uteroglobin promoter-targeted c-MYC expression in transgenic mice cause hyperplasia of Clara cells and malignant transformation of T-lymphoblasts and tubular epithelial cells (PMID:11817538)
• initiates illegitimate recombination of ribonucleotide reductase 2 gene (PMID:11840336)
• Acute hyperglycaemia induces an up-regulation of seven major genes, four of which were not previously reported in the literature. Northern blot analyses, performed on these 4 genes, confirm macroarrays results for alphav, beta4, c-myc, and MUC18. (PMID:11848444)
• Activation of c-MYC and c-MYB proto-oncogenes is associated with decreased apoptosis in tumor colon progression. (PMID:11848471)
• amplification in acute nonlymphocytic leukemia (PMID:11850082)
• Repression of alpha-fetoprotein gene expression under hypoxic conditions in human hepatoma cells: characterization of a negative hypoxia response element that mediates opposite effects of hypoxia inducible factor-1 and c-Myc. (PMID:11861398)
• The cytoplasmic domain of gp130 is involve the induction of c-myc expression and the cell proliferation in Meg-01 cell. (PMID:11877042)
• Retinoic acid-induced cell cycle arrest of human myeloid cell lines is associated with sequential down-regulation of c-Myc and cyclin E. (PMID:11877298)
• Scatter factor/hepatocyte growth factor stimulation of glioblastoma cell cycle progression through G(1) is c-Myc dependent and independent of p27 suppression, Cdk2 activation, or E2F1-dependent transcription. (PMID:11909963)
• complex with Nmi and BRCA1 inhibits c-Myc-induced human telomerase reverse transcriptase gene promoter activity in breast cancer (PMID:11916966)
• c-myc-induced apoptosis in polycystic kidney disease is independent of FasL/Fas interaction. (PMID:11956070)
• The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2 (PMID:11960382)
• estrogen and Myc negatively regulate EphA2 expression in mammary epithelial cells (PMID:11968011)
• A novel form of the RelA nuclear factor kappaB subunit is induced by and forms a complex with this proto-oncogene protein (PMID:12027803)
• overexpressed in acute myeloid leukemia while translocations associated with this gene are absent (PMID:12031912)
• The proto-oncogene c-myc in hematopoietic development and leukemogenesis (PMID:12032779)
• c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function (PMID:12049739)
• Overexpression of c-myc mRNA was found in an Achilles tendon clear cell sarcoma and may have a role in its malignant progression. (PMID:12072203)
• TRRAP binding and the recruitment of histone H3 and H4 acetyltransferase activities are required for the transactivation of a silent TERT gene in exponentially growing human fibroblasts by c-Myc or N-Myc protein. (PMID:12077335)
• Effects of fluid shear stress on expression of proto-oncogenes c-fos and c-myc in cultured human umbilical vein endothelial cells. (PMID:12082260)
• the in vitro effects of iron on the proliferation of a primary, human synovial fibroblast cell line and the involvement of c-myc in this process as a model for c-myc proto-oncogene expression in hemophilic synovitis (PMID:12130502)
• role of c-Myc increasing susceptibility to tumor necrosis factor mediated apoptosis (PMID:12149248)
• Myc activates transcription by stimulating elongation and that P-TEFb is a key mediator of this process (PMID:12177005)
• dysregulated beta-catenin may cause a transcriptional upregulation of the c-myc gene; the c-Myc protein expression appears to be further regulated by posttranscriptional mechanism(s) during neoplastic progression in colorectal adenocarcinomas (PMID:12209953)
• C-Myc may be a downstream target of anaplastic lymphoma kinase (ALK)signaling and its expression a defining characteristic of ALK-positive anaplastic large cell lymphomas (PMID:12213716)
• c-myc induces programmed cell death in a process requiring glutathione in human tumor cells (PMID:12226097)
• Amplifications of c-myc and CCND1 are associated with detrusor-muscle-invasive transitional cell carcinoma (PMID:12237776)
• results reveal a novel cytoskeletal function for Myc and indicate the feasibility of quantitative whole-proteome analysis in mammalian cells (PMID:12356725)
• This review describes the role of MYC in tumor progression (PMID:12360279)
• c-myc and c-erbB2 amplification in breast cancer (PMID:12362975)
• Marked intratumoral heterogeneity of this and cyclinD1 but not of c-erbB2 amplification in breast cancer (PMID:12379776)
• Beta-catenin mutations correlate with over expression of C-myc and cyclin D1 Genes in bladder cancer. (PMID:12394763)
• CD19+ cells from transgenic mice with a lamba-humanMYC construct driven by B-cell elements overexpressed both C-MYC and protein kinase A-Cbeta. (PMID:12420224)
• c-Myc promotes cell survival under stressful conditions. (PMID:12435808)
• the mechanism of apoptosis induced by c-myc gene in oral squamous cell (PMID:12452058)
• Reduction in the c-myc protein was correlated with neck metastasis in nasopharyngeal carcinoma. (PMID:12490316)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	mycb	ENSDARG00000007241
danio_rerio	myca	ENSDARG00000045695
mus_musculus	Myc	ENSMUSG00000022346
rattus_norvegicus	Myc	ENSRNOG00000004500

Paralogs (2): MYCL (ENSG00000116990), MYCN (ENSG00000134323)

Protein

Protein identifiers

Myc proto-oncogene protein — P01106 (reviewed: P01106)

Alternative names: Class E basic helix-loop-helix protein 39, Proto-oncogene c-Myc, Transcription factor p64

All UniProt accessions (6): A0A0B4J1R1, A0A494C1T8, P01106, H0YBG3, Q14899, Q16591

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5’-CAC[GA]TG-3’. Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis. Regulator of somatic reprogramming, controls self-renewal of embryonic stem cells. Functions with TAF6L to activate target gene expression through RNA polymerase II pause release. Positively regulates transcription of HNRNPA1, HNRNPA2 and PTBP1 which in turn regulate splicing of pyruvate kinase PKM by binding repressively to sequences flanking PKM exon 9, inhibiting exon 9 inclusion and resulting in exon 10 inclusion and production of the PKM M2 isoform.

Subunit / interactions. Efficient DNA binding requires dimerization with another bHLH protein. Binds DNA as a heterodimer with MAX. Interacts with TAF1C and SPAG9. Interacts with PARP10. Interacts with KDM5A and KDM5B. Interacts (when phosphorylated at Thr-73 and Ser-77) with FBXW7. Interacts with PIM2. Interacts with RIOX1. The heterodimer MYC:MAX interacts with ABI1; the interaction may enhance MYC:MAX transcriptional activity. Interacts with TRIM6. Interacts with NPM1; the binary complex is recruited to the promoter of MYC target genes and enhances their transcription. Interacts with CIP2A; leading to the stabilization of MYC. Interacts with NUP205. Interacts with HEATR1; the interaction is required for localization of MYC to the nucleolus.

Subcellular location. Nucleus. Nucleoplasm. Nucleolus. Cytoplasm. Chromosome.

Post-translational modifications. Phosphorylated by PRKDC. Phosphorylation at Ser-344 by PIM2 leads to the stabilization of MYC. Phosphorylation at Ser-77 by CDK2 prevents Ras-induced senescence. Phosphorylated at Ser-77 by DYRK2; this primes the protein for subsequent phosphorylation by GSK3B at Thr-73. Phosphorylation at Thr-73 and Ser-77 by GSK3 is required for ubiquitination and degradation by the proteasome. Dephosphorylation at multiple sites by the PNUTS-PP1 complex promotes MYC stability by preventing ubiquitination by the SCF(FBXW7) complex. Dephosphorylation at Ser-77 by protein phosphatase 2A (PPP2CA) promotes its degradation; interaction with PPP2CA is enhanced by AMBRA1. Ubiquitinated by the SCF(FBXW7) complex when phosphorylated at Thr-73 and Ser-77, leading to its degradation by the proteasome. In the nucleoplasm, ubiquitination is counteracted by USP28, which interacts with isoform 1 of FBXW7 (FBW7alpha), leading to its deubiquitination and preventing degradation. In the nucleolus, however, ubiquitination is not counteracted by USP28 but by USP36, due to the lack of interaction between isoform 3 of FBXW7 (FBW7gamma) and USP28, explaining the selective MYC degradation in the nucleolus. Also polyubiquitinated by the DCX(TRPC4AP) complex. Ubiquitinated by UBR5 when not forming a heterodimer with another bHLH protein, leading to its degradation: UBR5 recognizes and binds a degron that is only available upon heterodimer dissociation. Ubiquitinated by TRIM6 in a phosphorylation-independent manner.

Disease relevance. A chromosomal aberration involving MYC may be a cause of a form of B-cell chronic lymphocytic leukemia. Translocation t(8;12)(q24;q22) with BTG1. Burkitt lymphoma (BL) [MIM:113970] A form of undifferentiated malignant lymphoma commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. The gene represented in this entry is involved in disease pathogenesis. Chromosomal aberrations involving MYC are usually found in Burkitt lymphoma. Translocations t(8;14), t(8;22) or t(2;8) which juxtapose MYC to one of the heavy or light chain immunoglobulin gene loci.

Domain organisation. The 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.

Miscellaneous. Alternative translation initiation from an upstream, in-frame non-ATG (CTG) codon or a downstream ATG start site results in the production of 2 isoforms with distinct N-termini, shown in this entry as isoforms 2/3 and isoform 1, respectively. Produced by alternative translation initiation from a CTG codon, which is translated as Met. Produced by alternative translation initiation from a CTG codon, which is translated as Met, and alternative splicing.

Isoforms (3)

UniProt ID	Names	Canonical?
P01106-2	2, c-myc 1	yes
P01106-1	1, c-myc 2
P01106-3	3

RefSeq proteins (2): NP_001341799, NP_002458* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002418	Tscrpt_reg_Myc	Family
IPR003327	Myc-LZ	Domain
IPR011598	bHLH_dom	Domain
IPR012682	Tscrpt_reg_Myc_N	Domain
IPR036638	HLH_DNA-bd_sf	Homologous_superfamily
IPR050433	Myc_transcription_factors	Family

Pfam: PF00010, PF01056, PF02344

UniProt features (73 total): modified residue 23, sequence conflict 15, sequence variant 8, helix 5, region of interest 4, cross-link 4, mutagenesis site 4, compositionally biased region 3, splice variant 2, short sequence motif 2, chain 1, domain 1, glycosylation site 1

Structure

Experimental structures (PDB)

25 structures.

PDB	Method	Resolution (Å)
9QNH	X-RAY DIFFRACTION	1.3
6G6K	X-RAY DIFFRACTION	1.35
1NKP	X-RAY DIFFRACTION	1.8
8Q1N	X-RAY DIFFRACTION	1.84
4Y7R	X-RAY DIFFRACTION	1.9
8J2Q	X-RAY DIFFRACTION	1.92
5I4Z	X-RAY DIFFRACTION	1.95
8X8V	X-RAY DIFFRACTION	2
8X8S	X-RAY DIFFRACTION	2.04
1EE4	X-RAY DIFFRACTION	2.1
6G6L	X-RAY DIFFRACTION	2.2
6G6J	X-RAY DIFFRACTION	2.25
6E16	X-RAY DIFFRACTION	2.4
7T1Y	X-RAY DIFFRACTION	2.55
8WLG	X-RAY DIFFRACTION	2.55
6C4U	X-RAY DIFFRACTION	2.6
2OR9	X-RAY DIFFRACTION	2.7
5I50	X-RAY DIFFRACTION	2.7
7T1Z	X-RAY DIFFRACTION	2.77
6E24	X-RAY DIFFRACTION	3
8OTS	ELECTRON MICROSCOPY	3.3
8OTT	ELECTRON MICROSCOPY	3.3
1A93	SOLUTION NMR
1MV0	SOLUTION NMR
2A93	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P01106-F1	61.38	0.21

Antibody-complex structures (SAbDab): 1 — 2OR9

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (27): 21, 23, 73, 77, 86, 96, 158, 163, 166, 172, 174, 176, 290, 308, 329, 330, 332, 338, 344, 359 …

Glycosylation sites (1): 73

Mutagenesis-validated functional residues (4):

Position	Phenotype
73	impairs interaction with fbxw7 and subsequent degradation by the proteasome. normal inhibition of ras-induced senescence
77	impairs interaction with fbxw7 and subsequent degradation by the proteasome. impaired inhibition of ras-induced senescen
77	phospho-mimetic mutant; abolished regulation by ambra1.
450	abolished ubiquitination and degradation by the dcx(trpc4ap) complex.

Function

Pathways and Gene Ontology

Reactome pathways

62 pathways

ID	Pathway
R-HSA-1362277	Transcription of E2F targets under negative control by DREAM complex
R-HSA-201556	Signaling by ALK
R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription
R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants
R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
R-HSA-4411364	Binding of TCF/LEF:CTNNB1 to target gene promoters
R-HSA-5687128	MAPK6/MAPK4 signaling
R-HSA-5689880	Ub-specific processing proteases
R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling
R-HSA-69202	Cyclin E associated events during G1/S transition
R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry
R-HSA-8866911	TFAP2 (AP-2) family regulates transcription of cell cycle factors
R-HSA-8951430	RUNX3 regulates WNT signaling
R-HSA-9018519	Estrogen-dependent gene expression
R-HSA-9616222	Transcriptional regulation of granulopoiesis
R-HSA-9764562	Regulation of CDH1 mRNA translation by microRNAs
R-HSA-9818749	Regulation of NFE2L2 gene expression
R-HSA-9909649	Regulation of PD-L1(CD274) transcription
R-HSA-201722	Formation of the beta-catenin:TCF transactivating complex
R-HSA-4086398	Ca2+ pathway
R-HSA-4641265	Repression of WNT target genes
R-HSA-1266738	Developmental Biology
R-HSA-1280215	Cytokine Signaling in Immune system
R-HSA-1538133	G0 and Early G1
R-HSA-157118	Signaling by NOTCH
R-HSA-162582	Signal Transduction
R-HSA-1640170	Cell Cycle
R-HSA-1643685	Disease
R-HSA-168256	Immune System

MSigDB gene sets: 1045 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_CHROMOSOME_ORGANIZATION, REACTOME_SIGNALING_BY_NOTCH, MODULE_52, FUNG_IL2_SIGNALING_2, E2F_Q4_01, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_POSITIVE_REGULATION_OF_LYMPHOCYTE_APOPTOTIC_PROCESS, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_CELL_DEVELOPMENT, GOBP_SOMATIC_STEM_CELL_POPULATION_MAINTENANCE, GOBP_MUSCLE_TISSUE_DEVELOPMENT, BIOCARTA_TEL_PATHWAY, REACTOME_SIGNALING_BY_TGF_BETA_RECEPTOR_COMPLEX

GO Biological Process (65): G1/S transition of mitotic cell cycle (GO:0000082), negative regulation of transcription by RNA polymerase II (GO:0000122), MAPK cascade (GO:0000165), branching involved in ureteric bud morphogenesis (GO:0001658), B cell apoptotic process (GO:0001783), NK T cell proliferation (GO:0001866), positive regulation of mesenchymal cell proliferation (GO:0002053), positive regulation of B cell apoptotic process (GO:0002904), chromatin remodeling (GO:0006338), regulation of transcription by RNA polymerase II (GO:0006357), transcription by RNA polymerase II (GO:0006366), intracellular iron ion homeostasis (GO:0006879), DNA damage response (GO:0006974), positive regulation of cell population proliferation (GO:0008284), intrinsic apoptotic signaling pathway in response to DNA damage (GO:0008630), response to xenobiotic stimulus (GO:0009410), regulation of gene expression (GO:0010468), regulation of cell cycle process (GO:0010564), positive regulation of gene expression (GO:0010628), myotube differentiation (GO:0014902), Wnt signaling pathway (GO:0016055), rRNA metabolic process (GO:0016072), protein processing (GO:0016485), regulation of telomere maintenance (GO:0032204), positive regulation of telomere maintenance (GO:0032206), negative regulation of stress-activated MAPK cascade (GO:0032873), protein-DNA complex disassembly (GO:0032986), cellular response to UV (GO:0034644), cellular response to interferon-alpha (GO:0035457), skeletal muscle cell differentiation (GO:0035914), middle ear morphogenesis (GO:0042474), negative regulation of apoptotic process (GO:0043066), response to alkaloid (GO:0043279), pigmentation (GO:0043473), negative regulation of gene expression via chromosomal CpG island methylation (GO:0044027), fibroblast apoptotic process (GO:0044346), negative regulation of monocyte differentiation (GO:0045656), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), positive regulation of fibroblast proliferation (GO:0048146)

GO Molecular Function (20): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), core promoter sequence-specific DNA binding (GO:0001046), transcription coregulator binding (GO:0001221), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), DNA binding (GO:0003677), ubiquitin protein ligase binding (GO:0031625), identical protein binding (GO:0042802), protein-containing complex binding (GO:0044877), protein dimerization activity (GO:0046983), E-box binding (GO:0070888), DNA-binding transcription factor binding (GO:0140297), transcription regulator activator activity (GO:0140537), SCF ubiquitin ligase complex binding (GO:1905761), cis-regulatory region sequence-specific DNA binding (GO:0000987), DNA-binding transcription factor activity (GO:0003700), mRNA binding (GO:0003729), protein binding (GO:0005515), eukaryotic initiation factor eIF2 binding (GO:0071074)

GO Cellular Component (18): chromatin (GO:0000785), euchromatin (GO:0000791), nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), spindle (GO:0005819), nuclear body (GO:0016604), axon (GO:0030424), protein-containing complex (GO:0032991), perinuclear region of cytoplasm (GO:0048471), Myc-Max complex (GO:0071943), RNA polymerase II transcription repressor complex (GO:0090571), nuclear envelope (GO:0005635), chromosome (GO:0005694), cytoplasm (GO:0005737), rough endoplasmic reticulum (GO:0005791), membrane (GO:0016020), nucleoplasmic reticulum (GO:0044195)

Reactome top-level categories

Rollup of top-20 pathways:

Category	Pathways
G0 and Early G1	1
Signaling by Receptor Tyrosine Kinases	1
Signaling by NOTCH1	1
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	1
Signaling by NOTCH1 PEST Domain Mutants in Cancer	1
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	1
Formation of the beta-catenin:TCF transactivating complex	1
MAPK family signaling cascades	1
Deubiquitination	1
Signaling by Interleukins	1
G1/S Transition	1
S Phase	1
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	1
Transcriptional regulation by RUNX3	1
ESR-mediated signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	6
RNA polymerase II transcription regulatory region sequence-specific DNA binding	4
intracellular membraneless organelle	4
transcription cis-regulatory region binding	3
regulation of transcription by RNA polymerase II	2
transcription by RNA polymerase II	2
regulation of DNA-templated transcription	2
gene expression	2
regulation of gene expression	2
chromatin	2
transcription factor binding	2
DNA-binding transcription factor activity, RNA polymerase II-specific	2
protein binding	2
binding	2
transcription regulator activity	2
nuclear lumen	2
mitotic cell cycle	1
mitotic cell cycle phase transition	1
cell cycle G1/S phase transition	1
negative regulation of DNA-templated transcription	1
intracellular signaling cassette	1
branching morphogenesis of an epithelial tube	1
ureteric bud morphogenesis	1
lymphocyte apoptotic process	1
alpha-beta T cell proliferation	1
NK T cell activation	1
positive regulation of cell population proliferation	1
mesenchymal cell proliferation	1
regulation of mesenchymal cell proliferation	1
B cell apoptotic process	1
regulation of B cell apoptotic process	1
positive regulation of lymphocyte apoptotic process	1
chromatin organization	1
DNA-templated transcription	1
intracellular monoatomic cation homeostasis	1
inorganic ion homeostasis	1
cellular response to stress	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1

Protein interactions and networks

STRING

14230 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MYC	TP53	P04637	997
MYC	BRCA1	P38398	995
MYC	EP300	Q09472	994
MYC	TRRAP	Q9Y4A5	993
MYC	CDCA7L	Q96GN5	991
MYC	E2F1	Q01094	990
MYC	BIN1	O00499	989
MYC	MAX	P25912	987
MYC	ZNF346	Q9UL40	986
MYC	DNMT3A	Q9Y6K1	983
MYC	SMAD3	P84022	983
MYC	HIF1A	Q16665	982
MYC	IGF2BP1	Q9NZI8	980
MYC	ZBTB17	Q13105	976
MYC	KAT2B	Q92831	972
MYC	AMOTL1	Q8IY63	972

IntAct

560 interactions, top by confidence:

A	B	Type	Score
MAX	MYC	psi-mi:“MI:2364”(proximity)	0.980
MAX	MYC	psi-mi:“MI:0914”(association)	0.980
MYC	MAX	psi-mi:“MI:2364”(proximity)	0.980
MAX	MYC	psi-mi:“MI:0915”(physical association)	0.980
FBXW7	MYC	psi-mi:“MI:0915”(physical association)	0.870
MYC	ZBTB17	psi-mi:“MI:0915”(physical association)	0.780
ZBTB17	MYC	psi-mi:“MI:0915”(physical association)	0.780
ZBTB17	MYC	psi-mi:“MI:0407”(direct interaction)	0.780
MYC	CCAR2	psi-mi:“MI:0915”(physical association)	0.750
CCAR2	MYC	psi-mi:“MI:0915”(physical association)	0.750
MYC	MCM7	psi-mi:“MI:0915”(physical association)	0.730
MCM7	MYC	psi-mi:“MI:0915”(physical association)	0.730
MYC	HDAC1	psi-mi:“MI:0914”(association)	0.690
MYC	EFTUD2	psi-mi:“MI:0915”(physical association)	0.680
EFTUD2	MYC	psi-mi:“MI:0915”(physical association)	0.680
MYC	Max	psi-mi:“MI:0407”(direct interaction)	0.630
MYC	SNIP1	psi-mi:“MI:0915”(physical association)	0.630
SNIP1	MYC	psi-mi:“MI:0915”(physical association)	0.630

BioGRID (5818): USP37 (Affinity Capture-Western), MYC (Affinity Capture-Western), MYC (Reconstituted Complex), MYC (Biochemical Activity), MYC (Protein-RNA), MYC (Protein-RNA), MYC (Reconstituted Complex), MYC (Affinity Capture-Western), CREBBP (Affinity Capture-Western), MYC (Two-hybrid), MYC (Reconstituted Complex), CREBBP (Reconstituted Complex), MYC (Biochemical Activity), MYC (Biochemical Activity), MYC (Affinity Capture-Western)

ESM2 similar proteins: A1YG22, A2T7L5, B8XIA5, O54968, P01106, P01108, P01109, P01110, P06171, P06295, P06646, P09416, P0C0N8, P0C0N9, P10395, P12523, P12525, P15171, P21438, P22555, P23583, P23999, P35805, P49032, P49033, P49709, P52160, P68271, P68272, Q05404, Q16236, Q17103, Q28350, Q28566, Q29031, Q2HJ27, Q5NUA6, Q60795, Q64210, Q6DFC8

Diamond homologs: A1YG22, A2T7L5, B8XIA5, P01106, P01108, P01109, P01110, P03966, P04198, P06171, P06295, P06646, P09416, P0C0N8, P0C0N9, P10166, P10395, P12523, P12524, P15063, P15171, P18444, P20389, P21438, P22555, P23583, P23999, P24793, P26014, P28574, P49032, P49033, P49709, P52160, P52161, P52162, P52164, P61244, P61245, P68271

SIGNOR signaling

173 interactions.

A	Effect	B	Mechanism
MYC	“up-regulates quantity by expression”	CCNA2	“transcriptional regulation”
MYC	“up-regulates quantity by expression”	CCND1	“transcriptional regulation”
MYC	“up-regulates quantity by expression”	CDK4	“transcriptional regulation”
MYC	“up-regulates quantity by expression”	CDK6	“transcriptional regulation”
MYC	“down-regulates quantity by repression”	CDKN1A	“transcriptional regulation”
MYC	“down-regulates quantity by repression”	CDKN2A	“transcriptional regulation”
MYC	“down-regulates quantity by repression”	CDKN2B	“transcriptional regulation”
MYC	“up-regulates quantity by expression”	CUL1	“transcriptional regulation”
MYC	“down-regulates quantity by repression”	CDKN1B	“transcriptional regulation”
MYC	down-regulates	SMAD2
MYC	“down-regulates activity”	SMAD3	binding
GSK3B	“down-regulates quantity by destabilization”	MYC	phosphorylation
SMAD3	“down-regulates quantity by repression”	MYC	“transcriptional regulation”
GSK3A	“down-regulates quantity by destabilization”	MYC	phosphorylation
NOTCH1	“up-regulates quantity by expression”	MYC	“transcriptional regulation”
PPP2CB	down-regulates	MYC	dephosphorylation
USP28	up-regulates	MYC	deubiquitination
CTNNB1	“up-regulates quantity by expression”	MYC	“transcriptional regulation”
PIN1	up-regulates	MYC	binding
RBPJ/NOTCH	“up-regulates quantity by expression”	MYC	“transcriptional regulation”
SATB1	“down-regulates quantity by repression”	MYC	“transcriptional regulation”
MAPK8	“up-regulates activity”	MYC	phosphorylation
DOT1L	“up-regulates activity”	MYC	binding
DLX5	“up-regulates quantity”	MYC	“transcriptional regulation”
PLK1	“up-regulates activity”	MYC	phosphorylation
SCF-betaTRCP	“up-regulates quantity”	MYC	ubiquitination
FBXW7	“down-regulates quantity”	MYC	ubiquitination
SKP2	“down-regulates quantity”	MYC	ubiquitination

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 139 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of endogenous retroelements	5	17.2×	8e-04
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	5	14.0×	1e-03
SUMOylation of ubiquitinylation proteins	5	13.7×	1e-03
S Phase	8	13.6×	2e-05
Transport of Mature mRNA Derived from an Intronless Transcript	5	12.7×	2e-03
Regulation of MITF-M-dependent genes involved in pigmentation	5	12.4×	2e-03
Viral Messenger RNA Synthesis	5	12.1×	2e-03
snRNP Assembly	6	11.9×	8e-04

GO biological processes:

GO term	Partners	Fold	FDR
protein import into nucleus	8	8.8×	5e-04
chromatin remodeling	11	6.1×	5e-04
DNA repair	10	4.9×	2e-03
cell division	13	4.6×	5e-04

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 4 cancer types — AML, BL, MLYM, NHL.

Clinical variants and AI predictions

ClinVar

49 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	5
Likely pathogenic	1
Uncertain significance	11
Likely benign	3
Benign	5

Top pathogenic / likely-pathogenic (6)

Variant ID	HGVS	Classification
12574	NM_002467.6(MYC):c.214C>T (p.Pro72Ser)	Pathogenic
12575	NM_002467.6(MYC):c.302A>C (p.Asn101Thr)	Pathogenic
12576	NM_002467.6(MYC):c.162G>C (p.Glu54Asp)	Pathogenic
2658815	NM_002467.6(MYC):c.217A>G (p.Thr73Ala)	Pathogenic
599306	Single allele	Pathogenic
810340	GRCh37/hg19 8q24.21(chr8:128750494-128753204)x3	Likely pathogenic

SpliceAI

522 predictions. Top by Δscore:

Variant	Effect	Δscore
8:127739019:GGTAA:G	donor_loss	1.0000
8:127739020:G:GA	donor_loss	1.0000
8:127740392:A:AG	acceptor_gain	1.0000
8:127740393:A:AG	acceptor_gain	1.0000
8:127740394:A:G	acceptor_gain	1.0000
8:127740394:AGAG:A	acceptor_gain	1.0000
8:127740395:G:GA	acceptor_gain	1.0000
8:127740395:GA:G	acceptor_gain	1.0000
8:127740395:GAGG:G	acceptor_gain	1.0000
8:127740395:GAGGA:G	acceptor_gain	1.0000
8:127739015:CTCTG:C	donor_gain	0.9900
8:127739020:G:GG	donor_gain	0.9900
8:127740393:AAGAG:A	acceptor_gain	0.9900
8:127736622:AGGT:A	donor_loss	0.9800
8:127736623:GGT:G	donor_loss	0.9800
8:127736624:GTAA:G	donor_loss	0.9800
8:127736625:T:G	donor_loss	0.9800
8:127739016:TCTG:T	donor_gain	0.9800
8:127739018:TG:T	donor_gain	0.9800
8:127739019:GG:G	donor_gain	0.9800
8:127736610:T:TA	donor_gain	0.9700
8:127736611:A:AA	donor_gain	0.9700
8:127736620:CCAG:C	donor_gain	0.9700
8:127738247:GCAGC:G	acceptor_gain	0.9700
8:127739017:CTG:C	donor_gain	0.9700
8:127736624:G:GG	donor_gain	0.9600
8:127738247:GCA:G	acceptor_gain	0.9600
8:127738233:T:TA	acceptor_gain	0.9400
8:127738246:A:AG	acceptor_gain	0.9400
8:127738247:G:GG	acceptor_gain	0.9400

AlphaMissense

2989 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:127738410:T:A	W50R	1.000
8:127738410:T:C	W50R	1.000
8:127738411:G:C	W50S	1.000
8:127738412:G:C	W50C	1.000
8:127738412:G:T	W50C	1.000
8:127738419:T:C	F53L	1.000
8:127738420:T:C	F53S	1.000
8:127738421:C:A	F53L	1.000
8:127738421:C:G	F53L	1.000
8:127738657:A:C	D132A	1.000
8:127738657:A:T	D132V	1.000
8:127738665:T:A	W135R	1.000
8:127738665:T:C	W135R	1.000
8:127738667:G:C	W135C	1.000
8:127738667:G:T	W135C	1.000
8:127740713:C:A	H359N	1.000
8:127740713:C:G	H359D	1.000
8:127740715:C:A	H359Q	1.000
8:127740715:C:G	H359Q	1.000
8:127740718:C:A	N360K	1.000
8:127740718:C:G	N360K	1.000
8:127740725:G:A	E363K	1.000
8:127740726:A:T	E363V	1.000
8:127740727:G:C	E363D	1.000
8:127740727:G:T	E363D	1.000
8:127740728:C:A	R364S	1.000
8:127740729:G:C	R364P	1.000
8:127740735:G:C	R366T	1.000
8:127740735:G:T	R366M	1.000
8:127740736:G:C	R366S	1.000

dbSNP variants (sampled 300 via entrez): RS1000054901 (8:127739330 A>G), RS1000399492 (8:127739211 T>C,G), RS1000455991 (8:127738935 T>C,G), RS1000582000 (8:127734066 G>A), RS1000777844 (8:127734079 G>T), RS1001112229 (8:127738077 G>A,T), RS1001620886 (8:127739221 C>T), RS1001626410 (8:127733798 T>C), RS1001806624 (8:127741858 C>T), RS1002404249 (8:127743201 G>A,C,T), RS1002415654 (8:127743435 G>C,T), RS1002565108 (8:127737741 G>A,C,T), RS1002738773 (8:127735726 C>G), RS1002791428 (8:127735349 G>A,T), RS1003027230 (8:127737916 G>A,C,T)

Disease associations

OMIM: gene MIM:190080 | disease phenotypes: MIM:113970, MIM:236000, MIM:190350

GenCC curated gene-disease

Disease	Classification	Inheritance
Burkitt lymphoma	No Known Disease Relationship	Unknown

Mondo (5): Burkitt lymphoma (MONDO:0007243), cholesteatoma of middle ear (MONDO:0006533), classic Hodgkin lymphoma (MONDO:0009348), trichorhinophalangeal syndrome type I (MONDO:0008596), primary ovarian failure (MONDO:0005387)

Orphanet (4): Burkitt lymphoma (Orphanet:543), Classic Hodgkin lymphoma (Orphanet:391), Trichorhinophalangeal syndrome type 1 (Orphanet:77258), NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

18 total (18 of 18 shown, HPO-id order):

HPO	Term
HP:0000137	Abnormality of the ovary
HP:0001392	Abnormality of the liver
HP:0001442	Typified by somatic mosaicism
HP:0001732	Abnormality of the pancreas
HP:0001743	Abnormality of the spleen
HP:0002017	Nausea and vomiting
HP:0002027	Abdominal pain
HP:0002149	Hyperuricemia
HP:0002239	Gastrointestinal hemorrhage
HP:0002721	Immunodeficiency
HP:0002733	Abnormal lymph node morphology
HP:0003745	Sporadic
HP:0005214	Intestinal obstruction
HP:0005561	Abnormal bone marrow cell morphology
HP:0025435	Increased circulating lactate dehydrogenase concentration
HP:0030080	Burkitt lymphoma
HP:0032218	Decreased CD4+ T cell proportion
HP:0100649	Neoplasm of the oral cavity

GWAS associations

51 associations (top):

Study	Trait	p-value
GCST000231_2	Urinary bladder cancer	9.000000e-12
GCST000639_1	Urinary bladder cancer	7.000000e-12
GCST000802_5	Ovarian cancer	3.000000e-09
GCST000842_5	Bladder cancer	2.000000e-18
GCST001198_60	Multiple sclerosis	8.000000e-09
GCST001787_1	Colorectal cancer	1.000000e-11
GCST001937_9	Breast cancer	3.000000e-11
GCST001941_3	Ovarian cancer	3.000000e-12
GCST002073_17	Chronic lymphocytic leukemia	2.000000e-08
GCST002084_5	Allergic sensitization	5.000000e-10
GCST002273_1	Renal cell carcinoma	5.000000e-11
GCST002411_9	Colorectal cancer	8.000000e-13
GCST002413_8	Prostate cancer (early onset)	9.000000e-09
GCST002421_6	Prostate cancer	6.000000e-18
GCST002460_1	Urinary bladder cancer	2.000000e-07
GCST002553_3	Pancreatic cancer	1.000000e-07
GCST002636_5	Diffuse large B cell lymphoma	1.000000e-12
GCST002636_6	Diffuse large B cell lymphoma	4.000000e-11
GCST002702_10	Height	3.000000e-10
GCST002919_8	Colorectal cancer	6.000000e-15
GCST003017_15	Colorectal cancer	4.000000e-14
GCST003524_3	Endometrial cancer	3.000000e-09
GCST003524_8	Endometrial cancer	4.000000e-07
GCST003525_2	Endometrial endometrioid carcinoma	8.000000e-09
GCST003758_2	Pancreatic cancer	3.000000e-09
GCST004093_32	Prostate-specific antigen levels	7.000000e-21
GCST004094_5	Prostate-specific antigen levels (conditioned on lead SNPs)	2.000000e-10
GCST004166_6	Nonsyndromic cleft lip with cleft palate	8.000000e-16
GCST004988_223	Breast cancer	1.000000e-13
GCST005038_117	Allergic disease (asthma, hay fever or eczema)	6.000000e-14

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0005298	allergic sensitization measurement
EFO:1001514	endometrial endometrioid carcinoma
EFO:0003959	cleft lip
EFO:0009458	alcohol use disorder measurement
EFO:0004533	alkaline phosphatase measurement

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D002051	Burkitt Lymphoma	C01.925.256.466.313.165; C01.925.928.313.165; C04.557.386.480.150.165; C15.604.515.569.480.150.165; C20.683.515.761.480.150.165
D018424	Cholesteatoma, Middle Ear	C09.218.200; C17.800.428.260.300
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750
C536820	Trichorhinophalangeal Syndrome, Type I (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (7): CHEMBL1250348 (SINGLE PROTEIN), CHEMBL3301395 (PROTEIN COMPLEX), CHEMBL4106127 (PROTEIN-PROTEIN INTERACTION), CHEMBL4296141 (PROTEIN-PROTEIN INTERACTION), CHEMBL4888452 (PROTEIN-PROTEIN INTERACTION), CHEMBL5465202 (PROTEIN-PROTEIN INTERACTION), CHEMBL5465553 (PROTEIN-PROTEIN INTERACTION)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 70,355 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL165	RESVERATROL	3	60,144
CHEMBL4297458	EZOBRESIB	2	58
CHEMBL101309	AVASIMIBE	2	10,153

Clinical evidence (CIViC)

Drug × variant × indication: 3 predictive associations from 3 curated evidence items.

Variant	Therapy	Indication	Effect	Level	CIViC
MYC Overexpression	Ganetespib	Esophagus Squamous Cell Carcinoma	Sensitivity/Response	CIViC D	EID10151
MYC Overexpression	Olaparib + Cisplatin + Prexasertib	Lung Small Cell Carcinoma	Sensitivity/Response	CIViC D	EID3003
MYC Overexpression	JQ-1	Multiple Myeloma	Sensitivity/Response	CIViC D	EID5505

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

3 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs4645943	MYC		0.00	0
rs4645962	MYC		0.00	0
rs4645974	MYC		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Basic helix-loop-helix (BHLH) TFs

ChEMBL bioactivities

302 potent at pChembl≥5 of 425 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.70	IC50	0.2	nM	CHEMBL5089688
9.22	Kd	0.6	nM	CHEMBL4100737
9.22	IC50	0.6	nM	CHEMBL5084636
9.15	IC50	0.7	nM	EZOBRESIB
9.15	IC50	0.7	nM	CHEMBL5075294
9.10	Kd	0.8	nM	CHEMBL4098292
9.10	IC50	0.8	nM	CHEMBL5086429
9.00	IC50	1	nM	CHEMBL5091333
8.89	IC50	1.3	nM	CHEMBL5084198
8.77	Kd	1.7	nM	CHEMBL4105521
8.66	Kd	2.2	nM	CHEMBL4081781
8.62	IC50	2.4	nM	CHEMBL5090513
8.52	Kd	3	nM	CHEMBL4082223
8.47	IC50	3.4	nM	CHEMBL5090808
8.44	Kd	3.6	nM	CHEMBL4060316
8.44	Kd	3.6	nM	CHEMBL4097788
8.40	Kd	4	nM	CHEMBL4090075
8.34	Kd	4.6	nM	CHEMBL4087638
8.33	Kd	4.7	nM	CHEMBL4098292
8.30	Kd	5	nM	CHEMBL4063155
8.19	Kd	6.5	nM	CHEMBL4238599
8.16	IC50	6.9	nM	CHEMBL5080039
8.00	Kd	10	nM	CHEMBL4071241
7.96	Kd	11	nM	CHEMBL4079762
7.90	Kd	12.5	nM	CHEMBL4249055
7.87	Kd	13.4	nM	CHEMBL4238599
7.62	Kd	24	nM	CHEMBL4071241
7.38	IC50	42	nM	CHEMBL5069754
7.30	EC50	50.12	nM	CHEMBL5433447
7.28	Kd	53	nM	CHEMBL4098292
7.26	Kd	55	nM	CHEMBL4068997
6.96	Kd	110	nM	CHEMBL4059866
6.91	Kd	122	nM	CHEMBL4071241
6.80	EC50	158.5	nM	CHEMBL5406991
6.80	EC50	158.5	nM	CHEMBL5416237
6.72	IC50	190	nM	CHEMBL5435549
6.70	EC50	199.5	nM	CHEMBL5431243
6.70	EC50	199.5	nM	CHEMBL5427287
6.58	IC50	260	nM	CHEMBL4587215
6.54	IC50	291	nM	CHEMBL4541510
6.50	Kd	320	nM	CHEMBL4094669
6.46	IC50	343	nM	CHEMBL4560523
6.44	IC50	360	nM	CHEMBL4587175
6.41	IC50	393	nM	CHEMBL4575537
6.41	IC50	390	nM	CHEMBL5410251
6.40	Kd	400	nM	CHEMBL4084800
6.40	IC50	400	nM	CHEMBL4463878
6.40	EC50	398.1	nM	CHEMBL5088455
6.40	EC50	398.1	nM	CHEMBL5420545
6.40	EC50	398.1	nM	CHEMBL5404172

PubChem BioAssay actives

96 with measured affinity, of 420 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[7-(3,5-dimethyltriazol-4-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-3-yl]propan-2-ol	1807575: Inhibition of c-MYC (unknown origin)	ic50	0.0002	uM
2-[7-(3,5-dimethyltriazol-4-yl)-6-fluoro-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-3-yl]propan-2-ol	1807575: Inhibition of c-MYC (unknown origin)	ic50	0.0006	uM
2-[3-(3,5-dimethyltriazol-4-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol	1807575: Inhibition of c-MYC (unknown origin)	ic50	0.0007	uM
2-[8-fluoro-5-[(1S)-1-(3-fluoro-2-pyridinyl)butyl]-7-[3-methyl-5-(trideuteriomethyl)triazol-4-yl]pyrido[3,2-b]indol-3-yl]propan-2-ol	1807575: Inhibition of c-MYC (unknown origin)	ic50	0.0007	uM
2-[7-(3,5-dimethyltriazol-4-yl)-8-fluoro-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-3-yl]propan-2-ol	1807575: Inhibition of c-MYC (unknown origin)	ic50	0.0008	uM
2-[8-fluoro-7-[3-methyl-5-(trideuteriomethyl)triazol-4-yl]-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-3-yl]propan-2-ol	1807575: Inhibition of c-MYC (unknown origin)	ic50	0.0010	uM
2-[8-fluoro-5-[(S)-(3-fluoro-2-pyridinyl)-(oxan-4-yl)methyl]-7-[3-methyl-5-(trideuteriomethyl)triazol-4-yl]pyrido[3,2-b]indol-3-yl]propan-2-ol	1807575: Inhibition of c-MYC (unknown origin)	ic50	0.0013	uM
2-[8-fluoro-5-[(S)-(5-methyl-1,2-oxazol-3-yl)-(oxan-4-yl)methyl]-7-[3-methyl-5-(trideuteriomethyl)triazol-4-yl]pyrido[3,2-b]indol-3-yl]propan-2-ol	1807575: Inhibition of c-MYC (unknown origin)	ic50	0.0024	uM
2-[7-(3,5-dimethyltriazol-4-yl)-9-fluoro-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-3-yl]propan-2-ol	1807575: Inhibition of c-MYC (unknown origin)	ic50	0.0034	uM
4-[2-(furan-2-yl)-6-(4-nitrophenyl)-4-pyridinyl]benzamide	1398267: Binding affinity to His-tagged Myc (unknown origin) expressed in Escherichia coli BL21 by Bio-FET analysis	kd	0.0065	uM
2-[11-[3-methyl-5-(trideuteriomethyl)triazol-4-yl]-8-[(S)-oxan-4-yl(phenyl)methyl]-3,8,12-triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,5,9,11-hexaen-5-yl]propan-2-ol	1807575: Inhibition of c-MYC (unknown origin)	ic50	0.0069	uM
4-[2-(furan-2-yl)-6-[4-(1,3-thiazol-2-yl)phenyl]-4-pyridinyl]benzamide	1398267: Binding affinity to His-tagged Myc (unknown origin) expressed in Escherichia coli BL21 by Bio-FET analysis	kd	0.0125	uM
2-[8-chloro-7-[3-methyl-5-(trideuteriomethyl)triazol-4-yl]-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-3-yl]propan-2-ol	1807575: Inhibition of c-MYC (unknown origin)	ic50	0.0420	uM
3-[6-(diethylamino)-3-pyridinyl]-4-(2-ethoxyethyl)-1H-quinolin-2-one	2012024: Inhibition of human c-Myc in human Daudi cells assessed as decrease in c-Myc protein expression level incubated for 24 hrs by HTRF assay	ec50	0.0501	uM
5-[4,5-dibromo-1-(2-ethoxyethyl)imidazol-2-yl]-N,N-diethylpyridin-2-amine	2012024: Inhibition of human c-Myc in human Daudi cells assessed as decrease in c-Myc protein expression level incubated for 24 hrs by HTRF assay	ec50	0.1585	uM
5-[3-(2-ethoxyethyl)quinolin-2-yl]-N,N-diethylpyridin-2-amine	2012024: Inhibition of human c-Myc in human Daudi cells assessed as decrease in c-Myc protein expression level incubated for 24 hrs by HTRF assay	ec50	0.1585	uM
3-[3-[[2,6-difluoro-4-(3-fluorosulfonylphenyl)phenyl]methylcarbamoyl]-6-methyl-4-oxopyridazin-1-yl]benzoic acid	2003645: Inhibition of N-terminal his-tagged WDR5 (1 to 334 residues) (unknown origin)/Biotin tagged Myc (256-268 residues) (unknown origin) interaction measured after 1 hrs by HTRF assay	ic50	0.1900	uM
5-[4-(2-ethoxyethyl)isoquinolin-3-yl]-N,N-diethylpyridin-2-amine	2012024: Inhibition of human c-Myc in human Daudi cells assessed as decrease in c-Myc protein expression level incubated for 24 hrs by HTRF assay	ec50	0.1995	uM
3-[6-(diethylamino)-3-pyridinyl]-4-(2-ethoxyethyl)-1-methylquinolin-2-one	2012024: Inhibition of human c-Myc in human Daudi cells assessed as decrease in c-Myc protein expression level incubated for 24 hrs by HTRF assay	ec50	0.1995	uM
3-[3,5-difluoro-4-[[(6-methyl-4-oxo-1-phenylpyridazine-3-carbonyl)amino]methyl]phenyl]benzenesulfonyl fluoride	2003645: Inhibition of N-terminal his-tagged WDR5 (1 to 334 residues) (unknown origin)/Biotin tagged Myc (256-268 residues) (unknown origin) interaction measured after 1 hrs by HTRF assay	ic50	0.3900	uM
5-[1-(2-ethoxyethyl)benzimidazol-2-yl]-N,N-diethylpyridin-2-amine	2012024: Inhibition of human c-Myc in human Daudi cells assessed as decrease in c-Myc protein expression level incubated for 24 hrs by HTRF assay	ec50	0.3981	uM
N,N-diethyl-5-[3-[(2-methyl-1,3-oxazol-4-yl)methyl]imidazo[1,2-b]pyridazin-2-yl]pyridin-2-amine	2012024: Inhibition of human c-Myc in human Daudi cells assessed as decrease in c-Myc protein expression level incubated for 24 hrs by HTRF assay	ec50	0.3981	uM
4-[[2-[6-[(2S,5S)-2,5-dimethylpyrrolidin-1-yl]-3-pyridinyl]imidazo[1,2-b]pyridazin-3-yl]methyl]-2-methyl-1,3-oxazole	2012024: Inhibition of human c-Myc in human Daudi cells assessed as decrease in c-Myc protein expression level incubated for 24 hrs by HTRF assay	ec50	0.3981	uM
N,N-diethyl-5-[1-[(2-methyl-1,3-oxazol-4-yl)methyl]benzimidazol-2-yl]pyridin-2-amine	2012024: Inhibition of human c-Myc in human Daudi cells assessed as decrease in c-Myc protein expression level incubated for 24 hrs by HTRF assay	ec50	0.5012	uM
N,N-diethyl-5-[3-[(2-methyl-1,3-oxazol-4-yl)methyl]indazol-2-yl]pyridin-2-amine	2012024: Inhibition of human c-Myc in human Daudi cells assessed as decrease in c-Myc protein expression level incubated for 24 hrs by HTRF assay	ec50	0.5012	uM
3-[3-[[2,6-difluoro-4-[(3S)-3-fluoropyrrolidin-1-yl]phenyl]methylcarbamoyl]-6-methyl-4-oxopyridazin-1-yl]benzoic acid	2003645: Inhibition of N-terminal his-tagged WDR5 (1 to 334 residues) (unknown origin)/Biotin tagged Myc (256-268 residues) (unknown origin) interaction measured after 1 hrs by HTRF assay	ic50	0.6400	uM
N-[[2,6-difluoro-4-[(3R)-3-fluoropyrrolidin-1-yl]phenyl]methyl]-6-methyl-4-oxo-1-phenylpyridazine-3-carboxamide	2003645: Inhibition of N-terminal his-tagged WDR5 (1 to 334 residues) (unknown origin)/Biotin tagged Myc (256-268 residues) (unknown origin) interaction measured after 1 hrs by HTRF assay	ic50	0.7800	uM
N-[[4-(3,3-difluoropiperidin-1-yl)-2,6-difluorophenyl]methyl]-6-methyl-4-oxo-1-phenylpyridazine-3-carboxamide	2003645: Inhibition of N-terminal his-tagged WDR5 (1 to 334 residues) (unknown origin)/Biotin tagged Myc (256-268 residues) (unknown origin) interaction measured after 1 hrs by HTRF assay	ic50	0.8200	uM
[2-amino-4-(4-bromophenyl)-1,3-thiazol-5-yl] thiocyanate	2120491: Disruption of WDR5/5-FAM-labelled MYC (261 to 267 residues)(unknown origin) interaction incubated for 120 mins by FP assay	ki	0.9000	uM
3-[3,5-difluoro-4-[[(6-methyl-4-oxo-1-phenylpyridazine-3-carbonyl)amino]methyl]phenyl]benzenesulfonic acid	2003645: Inhibition of N-terminal his-tagged WDR5 (1 to 334 residues) (unknown origin)/Biotin tagged Myc (256-268 residues) (unknown origin) interaction measured after 1 hrs by HTRF assay	ic50	0.9100	uM
1-(3-carbamoylphenyl)-N-[[2,6-difluoro-4-[(3S)-3-fluoropyrrolidin-1-yl]phenyl]methyl]-6-methyl-4-oxopyridazine-3-carboxamide	2003645: Inhibition of N-terminal his-tagged WDR5 (1 to 334 residues) (unknown origin)/Biotin tagged Myc (256-268 residues) (unknown origin) interaction measured after 1 hrs by HTRF assay	ic50	0.9500	uM
[2-amino-4-[4-(methylcarbamoyl)phenyl]-1,3-thiazol-5-yl] thiocyanate	2120491: Disruption of WDR5/5-FAM-labelled MYC (261 to 267 residues)(unknown origin) interaction incubated for 120 mins by FP assay	ki	1.0000	uM
N-[[2,6-difluoro-4-[(3S)-3-fluoropyrrolidin-1-yl]phenyl]methyl]-6-methyl-4-oxo-1-phenylpyridazine-3-carboxamide	2003645: Inhibition of N-terminal his-tagged WDR5 (1 to 334 residues) (unknown origin)/Biotin tagged Myc (256-268 residues) (unknown origin) interaction measured after 1 hrs by HTRF assay	ic50	1.2000	uM
[4-(4-chlorophenyl)-2-(methylamino)-1,3-thiazol-5-yl] thiocyanate	2120491: Disruption of WDR5/5-FAM-labelled MYC (261 to 267 residues)(unknown origin) interaction incubated for 120 mins by FP assay	ki	1.2000	uM
3-[3-[[2,6-difluoro-4-[(3R)-3-fluoropyrrolidin-1-yl]phenyl]methylcarbamoyl]-6-methyl-4-oxopyridazin-1-yl]benzoic acid	2003645: Inhibition of N-terminal his-tagged WDR5 (1 to 334 residues) (unknown origin)/Biotin tagged Myc (256-268 residues) (unknown origin) interaction measured after 1 hrs by HTRF assay	ic50	1.2300	uM
5-[3-(2-ethoxyethyl)quinoxalin-2-yl]-N,N-diethylpyridin-2-amine	2012024: Inhibition of human c-Myc in human Daudi cells assessed as decrease in c-Myc protein expression level incubated for 24 hrs by HTRF assay	ec50	1.2589	uM
[2-amino-4-(4-chlorophenyl)-1,3-thiazol-5-yl] thiocyanate	2120491: Disruption of WDR5/5-FAM-labelled MYC (261 to 267 residues)(unknown origin) interaction incubated for 120 mins by FP assay	ki	1.3000	uM
2-[3-[3-[[2,6-difluoro-4-[(3R)-3-fluoropyrrolidin-1-yl]phenyl]methylcarbamoyl]-6-methyl-4-oxopyridazin-1-yl]phenyl]acetic acid	2003645: Inhibition of N-terminal his-tagged WDR5 (1 to 334 residues) (unknown origin)/Biotin tagged Myc (256-268 residues) (unknown origin) interaction measured after 1 hrs by HTRF assay	ic50	1.4300	uM
[2-amino-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl] thiocyanate	2120491: Disruption of WDR5/5-FAM-labelled MYC (261 to 267 residues)(unknown origin) interaction incubated for 120 mins by FP assay	ki	1.5000	uM
N-[[2,6-difluoro-4-(3-oxocyclohexen-1-yl)phenyl]methyl]-6-methyl-4-oxo-1-phenylpyridazine-3-carboxamide	2003645: Inhibition of N-terminal his-tagged WDR5 (1 to 334 residues) (unknown origin)/Biotin tagged Myc (256-268 residues) (unknown origin) interaction measured after 1 hrs by HTRF assay	ic50	1.5800	uM
N,N-diethyl-5-[3-[(2-methyl-1,3-oxazol-4-yl)methyl]pyrazolo[1,5-a]pyridin-2-yl]pyridin-2-amine	2012024: Inhibition of human c-Myc in human Daudi cells assessed as decrease in c-Myc protein expression level incubated for 24 hrs by HTRF assay	ec50	1.5849	uM
3-[(9-amino-7-methoxyacridin-3-yl)diazenyl]pyridine-2,6-diamine	2074200: Binding affinity to CM5 sensor chip immobilized MYC bHLHZip domain (unknown origin) assessed as dissociation constant by SPR analysis	kd	1.6000	uM
[4-(4-chlorophenyl)-2-(2-methylpropanoylamino)-1,3-thiazol-5-yl] thiocyanate	2120491: Disruption of WDR5/5-FAM-labelled MYC (261 to 267 residues)(unknown origin) interaction incubated for 120 mins by FP assay	ki	1.6000	uM
methyl 4-(2-amino-5-thiocyanato-1,3-thiazol-4-yl)benzoate	2120491: Disruption of WDR5/5-FAM-labelled MYC (261 to 267 residues)(unknown origin) interaction incubated for 120 mins by FP assay	ki	1.7000	uM
benzo[a]phenazin-5-ol	2074198: Binding affinity to MYC/MAX (unknown origin) by PCA analysis	ic50	1.8000	uM
1-(3-carbamoylphenyl)-N-[[2,6-difluoro-4-[(3R)-3-fluoropyrrolidin-1-yl]phenyl]methyl]-6-methyl-4-oxopyridazine-3-carboxamide	2003645: Inhibition of N-terminal his-tagged WDR5 (1 to 334 residues) (unknown origin)/Biotin tagged Myc (256-268 residues) (unknown origin) interaction measured after 1 hrs by HTRF assay	ic50	1.9300	uM
4-[6-(furan-2-yl)-4-[4-(2H-tetrazol-5-yl)phenyl]-2-pyridinyl]benzonitrile	1398268: Binding affinity to ATG-Myc (unknown origin) expressed in CEF cells assessed as inhibition of microtumor formation	ic50	2.0000	uM
[2-amino-4-(4-hydroxyphenyl)-1,3-thiazol-5-yl] thiocyanate	2120491: Disruption of WDR5/5-FAM-labelled MYC (261 to 267 residues)(unknown origin) interaction incubated for 120 mins by FP assay	ki	2.4000	uM
N-[[4-(3,3-dimethylpiperidin-1-yl)-2,6-difluorophenyl]methyl]-6-methyl-4-oxo-1-phenylpyridazine-3-carboxamide	2003645: Inhibition of N-terminal his-tagged WDR5 (1 to 334 residues) (unknown origin)/Biotin tagged Myc (256-268 residues) (unknown origin) interaction measured after 1 hrs by HTRF assay	ic50	2.4600	uM
3-[3,5-difluoro-4-[[(6-methyl-4-oxo-1-phenylpyridazine-3-carbonyl)amino]methyl]phenyl]benzoic acid	2003645: Inhibition of N-terminal his-tagged WDR5 (1 to 334 residues) (unknown origin)/Biotin tagged Myc (256-268 residues) (unknown origin) interaction measured after 1 hrs by HTRF assay	ic50	2.4800	uM

CTD chemical–gene interactions

546 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	affects response to substance, decreases expression, increases reaction, decreases reaction, increases expression (+5 more)	60
Estradiol	increases reaction, affects reaction, decreases expression, decreases reaction, increases expression (+4 more)	39
Arsenic Trioxide	increases activity, increases reaction, affects reaction, affects methylation, increases expression (+5 more)	34
Resveratrol	decreases expression, affects reaction, increases activity, increases reaction, increases expression (+3 more)	23
sodium arsenite	decreases expression, increases abundance, decreases reaction, increases expression, affects expression (+2 more)	18
Tretinoin	affects cotreatment, decreases expression, increases reaction, affects expression, affects reaction	17
Cisplatin	affects cotreatment, decreases expression, decreases reaction, increases abundance, decreases response to substance (+4 more)	13
bisphenol A	increases expression, affects cotreatment, decreases expression, affects reaction, increases reaction (+2 more)	12
Fulvestrant	decreases reaction, increases expression, affects cotreatment, decreases expression	10
Doxorubicin	decreases activity, affects cotreatment, affects binding, increases response to substance, affects expression (+3 more)	10
Quercetin	increases reaction, increases activity, increases expression, decreases expression, decreases reaction	9
Valproic Acid	affects cotreatment, decreases expression, affects expression, decreases methylation, increases expression	9
Cadmium	increases reaction, decreases reaction, increases abundance, increases expression, increases stability (+1 more)	8
Fluorouracil	affects cotreatment, affects expression, decreases expression, increases expression, affects response to substance (+2 more)	8
Tamoxifen	affects reaction, affects expression, increases expression, increases activity, affects binding (+4 more)	8
Cadmium Chloride	affects binding, increases reaction, decreases expression, increases stability, decreases reaction (+4 more)	8
trichostatin A	affects cotreatment, affects expression, increases expression, decreases expression	7
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	decreases reaction, increases expression, decreases expression, increases degradation, increases reaction	7
Calcitriol	decreases expression, affects cotreatment	7
Niclosamide	increases reaction, affects binding, increases expression, affects cotreatment, decreases reaction (+1 more)	7
Lithium Chloride	increases reaction, affects expression, affects reaction, decreases reaction, increases expression (+1 more)	7
5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one	decreases activity, affects binding, increases reaction, decreases expression, decreases reaction (+1 more)	6
Decitabine	affects cotreatment, increases expression, decreases expression	6
Vorinostat	decreases expression, decreases reaction, increases expression, affects cotreatment	6
Oxygen	decreases expression, affects reaction, increases expression, increases degradation, increases reaction (+7 more)	6
Tetradecanoylphorbol Acetate	affects cotreatment, decreases reaction, increases expression, affects reaction, decreases expression (+1 more)	6
Paclitaxel	decreases reaction, increases expression, affects response to substance, decreases response to substance, affects cotreatment (+1 more)	6
afimoxifene	decreases reaction, increases expression	5
Curcumin	decreases expression, affects cotreatment, affects expression, decreases reaction, increases expression	5
Tetrachlorodibenzodioxin	affects cotreatment, increases expression, affects expression, affects localization	5

ChEMBL screening assays

202 unique, capped per target: 202 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2318154	Binding	Ratio of 10074-G5 IC50 to compound IC50 for inhibition of recombinant His6-tagged c-Myc bHLH-ZIP domain (353 to 437 amino acid residues) (unknown origin)	Pharmacophore identification of c-Myc inhibitor 10074-G5. — Bioorg Med Chem Lett

Cellosaurus cell lines

610 cell lines: 539 cancer cell line, 56 transformed cell line, 9 telomerase immortalized cell line, 3 conditionally immortalized cell line, 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_0008	Daudi	Cancer cell line	Male
CVCL_0511	Raji	Cancer cell line	Male
CVCL_0597	Ramos	Cancer cell line	Male
CVCL_0R19	B-THP-1	Cancer cell line	Male
CVCL_0R20	B-THP-1/DC-SIGN	Cancer cell line	Male
CVCL_0R22	Raji/DC-SIGN	Cancer cell line	Male
CVCL_1101	CA46	Cancer cell line	Male
CVCL_1424	MOLT-16	Cancer cell line	Female
CVCL_1524	NCI-H2087	Cancer cell line	Male
CVCL_1646	Ramos.2G6.4C10	Cancer cell line	Male

Clinical trials (associated diseases)

111 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00199082	PHASE4	COMPLETED	Newly Diagnosed Mature B-ALL, Burkitt’s Lymphoma and Other High-grade Lymphoma in Adults
NCT05518383	PHASE4	RECRUITING	B-cell Mature Non-Hodgkin’s Lymphoma Treatment Protocol in Children and Adolescents 2021
NCT00180882	PHASE3	UNKNOWN	LMBA02 Protocol for Patients With a Burkitt Lymphoma
NCT01597778	PHASE3	COMPLETED	Double Cord Versus Haploidentical (BMT CTN 1101)
NCT05020392	PHASE3	UNKNOWN	Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma
NCT00001237	PHASE2	COMPLETED	Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas
NCT00001337	PHASE2	COMPLETED	Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin’s Lymphoma
NCT00126191	PHASE2	TERMINATED	Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
NCT00180895	PHASE2	TERMINATED	Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL
NCT00183976	PHASE2	TERMINATED	Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin’s Lymphomas
NCT00388193	PHASE2	COMPLETED	Rituximab Combined With Chemotherapy in Burkitt’s Lymphoma
NCT00669877	PHASE2	COMPLETED	Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt’s and Burkitt’s -Like Leukemia/Lymphoma
NCT00719888	PHASE2	COMPLETED	Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
NCT00807495	PHASE2	COMPLETED	Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin’s Lymphoma
NCT00849147	PHASE2	COMPLETED	Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
NCT00864227	PHASE2	COMPLETED	Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
NCT01028716	PHASE2	TERMINATED	Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01092182	PHASE2	COMPLETED	Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
NCT01093586	PHASE2	COMPLETED	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01109069	PHASE2	COMPLETED	Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
NCT01177371	PHASE2	COMPLETED	High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
NCT01290120	PHASE2	COMPLETED	Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt’s Non-Hodgkin Lymphoma
NCT01314014	PHASE2	COMPLETED	Imexon for Relapsed Follicular and Aggressive Lymphomas
NCT01363128	PHASE2	COMPLETED	Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT01434472	PHASE2	TERMINATED	High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
NCT01516593	PHASE2	COMPLETED	Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma
NCT01529827	PHASE2	COMPLETED	Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01859819	PHASE2	COMPLETED	Treatment for Advanced B-Cell Lymphoma
NCT02199184	PHASE2	COMPLETED	Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT02393157	PHASE2	RECRUITING	Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
NCT02661035	PHASE2	COMPLETED	Allo HSCT Using RIC for Hematological Diseases
NCT02722668	PHASE2	COMPLETED	UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
NCT02776891	PHASE2	WITHDRAWN	A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma
NCT02991898	PHASE2	TERMINATED	Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
NCT03038672	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
NCT03136146	PHASE2	RECRUITING	Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
NCT03314974	PHASE2	RECRUITING	Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
NCT03674411	PHASE2	ACTIVE_NOT_RECRUITING	Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
NCT04191187	PHASE2	COMPLETED	Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
NCT04195633	PHASE2	RECRUITING	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies